Faith E Davies

Faith E Davies

UNVERIFIED PROFILE

Are you Faith E Davies?   Register this Author

Register author
Faith E Davies

Faith E Davies

Publications by authors named "Faith E Davies"

Are you Faith E Davies?   Register this Author

100Publications

4095Reads

50Profile Views

Toward personalized treatment in multiple myeloma based on molecular characteristics.

Blood 2019 02 26;133(7):660-675. Epub 2018 Dec 26.

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-09
Publisher Site
http://dx.doi.org/10.1182/blood-2018-09-825331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384187PMC
February 2019

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Nat Commun 2019 01 10;10(1):213. Epub 2019 Jan 10.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-08107-8
Publisher Site
http://dx.doi.org/10.1038/s41467-018-08107-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328616PMC
January 2019

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Nat Commun 2018 09 13;9(1):3707. Epub 2018 Sep 13.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-04989-w
Publisher Site
http://dx.doi.org/10.1038/s41467-018-04989-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137048PMC
September 2018

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.

BMC Cancer 2018 Jul 6;18(1):724. Epub 2018 Jul 6.

Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4602-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035431PMC
July 2018

Practical Considerations for Antibodies in Myeloma.

Am Soc Clin Oncol Educ Book 2018 May;38:667-674

From the Department of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; International Myeloma Foundation, North Hollywood, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_205443DOI Listing
May 2018

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling.

Cell Signal 2018 04 9;44:127-137. Epub 2018 Jan 9.

The Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2018.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562199PMC
April 2018

Cardiovascular complications of multiple myeloma in the elderly.

Expert Rev Cardiovasc Ther 2017 Dec 27;15(12):933-943. Epub 2017 Nov 27.

b Department of Cardiovascular Medicine , Department of Medicine University of Arkansas Medical Sciences , Little Rock , AR , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14779072.2017.1409114DOI Listing
December 2017

Is molecular remission the goal of multiple myeloma therapy?

Authors:
Faith E Davies

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):205-211

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142553PMC
December 2017

Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.

Cancer Lett 2017 09 20;403:206-215. Epub 2017 Jun 20.

Clinical and Experimental Oncology Department, Federal University of São Paulo, UNIFESP, Brazil. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2017.06.016DOI Listing
September 2017

Immunologic approaches for the treatment of multiple myeloma.

Cancer Treat Rev 2017 Apr 6;55:190-199. Epub 2017 Apr 6.

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604432PMC
April 2017

Update on the optimal use of bortezomib in the treatment of multiple myeloma.

Cancer Manag Res 2017 2;9:51-63. Epub 2017 Mar 2.

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S105163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338851PMC
March 2017

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Immunotherapy 2016 17;8(3):367-84. Epub 2016 Feb 17.

Myeloma Institute, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.15.118DOI Listing
December 2016

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

J Clin Oncol 2015 Nov 17;33(33):3911-20. Epub 2015 Aug 17.

Brian A. Walker, Eileen M. Boyle, Christopher P. Wardell, Alex Murison, Dil B. Begum, Nasrin M. Dahir, Paula Z. Proszek, David C. Johnson, Martin F. Kaiser, Lorenzo Melchor, Lauren I. Aronson, Charlotte Pawlyn, Fabio Mirabella, John R. Jones, Annamaria Brioli, Faith E. Davies, and Gareth J. Morgan, The Institute of Cancer Research, London; Matthew Scales, The Institute of Cancer Research, Surrey; David A. Cairns, Walter M. Gregory, and Ana Quartilho, University of Leeds; Gordon Cook, St James's University Hospital, Leeds; Mark T. Drayson, University of Birmingham, Birmingham; Nigel Russell, Nottingham University Hospital, Nottingham; Graham H. Jackson, Newcastle University, Newcastle upon Tyne, United Kingdom; Aneta Mikulasova, Masaryk University, Brno, Czech Republic; and Xavier Leleu, Hôpital C. Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.1503
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.1503DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485456PMC
November 2015

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.

Oncotarget 2015 Jul;6(19):17314-27

Haemato-Oncology Research Unit, Division of Molecular Pathology, Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627310PMC
http://dx.doi.org/10.18632/oncotarget.1168DOI Listing
July 2015

Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress.

Mol Cell Biol 2015 Jun 13;35(12):2186-202. Epub 2015 Apr 13.

Divisions of Cancer Therapeutics and Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00013-15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438243PMC
June 2015

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.

Genes Chromosomes Cancer 2015 Feb 7;54(2):91-8. Epub 2014 Oct 7.

Division of Molecular Pathology, The Institute of Cancer Research, London, UK; Service des maladies du Sang, Hopital Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310140PMC
February 2015

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

J Clin Oncol 2015 Feb 20;33(6):657-64. Epub 2015 Jan 20.

Meletios A. Dimopoulos and Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Jens Hillengass and Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Saad Usmani, Carolinas Healthcare System, Charlotte, NC; Elena Zamagni and Michele Cavo, Bologna University School of Medicine, Bologna; Antonio Palumbo, S. Giovanni Battista Hospital, University of Turin, Turin, Italy; Suzanne Lentzsch, Columbia University College of Physicians and Surgeons, New York, NY; Faith E. Davies, Institute of Cancer Research, Sutton, United Kingdom; Noopur Raje, Massachusetts General Hospital Cancer Center; Kenneth Anderson, Dana-Farber Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Orhan Sezer, Memorial Sisli Hospital, Istanbul, Turkey; Sonja Zweegman, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, the Netherlands; Jatin Shah, MD Anderson Cancer Center, Houston, TX; Ashraf Badros, University of Maryland Medical Center, Baltimore, MD; Kazuyuki Shimizu, Tokai Central Hospital, Kakamigahara, Japan; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; Chor-Sang Chim, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region; Jian Hou, Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Artur Jurczyszyn, University Hospital, Krakow, Poland; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Bart Barlogie, University of Arkansas for Medical Sciences, Little Rock, AR; G. David Roodman, Indiana University School of Medicine, Indianapolis, IN; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; and Brian G.M. Durie, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.9961DOI Listing
February 2015

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.

Leuk Lymphoma 2014 Nov 22;55(11):2665-8. Epub 2014 Apr 22.

Myeloma Research Centre, Division of Molecular Pathology, The Institute of Cancer Research , London , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.900765DOI Listing
November 2014

Biology and treatment of myeloma.

Clin Lymphoma Myeloma Leuk 2014 Sep;14 Suppl:S65-70

Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.06.011DOI Listing
September 2014

Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.

Radiology 2014 Jun 21;271(3):785-94. Epub 2014 Jan 21.

From the Departments of Magnetic Resonance Imaging (S.L.G., C.M., D.J.C., V.A.M., C.J.S., N.M.D.) and Haemato-oncology (S.W., F.E.D., G.J.M.), Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, England; and Departments of Clinical Magnetic Resonance (D.J.C., N.M.D.) and Molecular Pathology (F.E.D., G.J.M.), Institute of Cancer Research, Sutton, Surrey, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.13131529DOI Listing
June 2014

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

J Natl Cancer Inst 2014 Apr 14;106(4):dju033. Epub 2014 Mar 14.

Affiliations of authors: Division of Radiotherapy and Imaging (TJG, NT, TJS, SPR), Cancer Research UK Cancer Therapeutics Unit (GB, MC, SM, GA, JdB, SAE, FED), and Molecular Pathology (FED), Institute of Cancer Research and Royal Marsden NHS Trust, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju033DOI Listing
April 2014

Current and potential epigenetic targets in multiple myeloma.

Epigenomics 2014 Apr;6(2):215-28

Centre for Myeloma Research, Institute of Cancer Research, 15 Cotswold Rd, Sutton, SM2 5NG, UK.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/epi.14.12
Publisher Site
http://dx.doi.org/10.2217/epi.14.12DOI Listing
April 2014

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

Health Qual Life Outcomes 2014 Mar 11;12:35. Epub 2014 Mar 11.

Evidera, 7575 Trans-Canada Highway, Suite 500, H4T 1V6 Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1477-7525-12-35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007827PMC
March 2014

Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.

Clin Cancer Res 2013 Nov 30;19(21):6030-8. Epub 2013 Aug 30.

Authors' Affiliations: Institute of Cancer Research, Royal Marsden Hospital, London; Clinical Trials Research Unit, University of Leeds; St James's University Hospital, Leeds; University of Birmingham, Birmingham; Wessex Regional Genetics Laboratory, University of Southampton, Salisbury; and University of Newcastle, Newcastle-upon-Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2013/08/
Web Search
http://clincancerres.aacrjournals.org/content/19/21/6030.ful
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-3211DOI Listing
November 2013

Role of thalidomide in the treatment of patients with multiple myeloma.

Crit Rev Oncol Hematol 2013 Oct 1;88 Suppl 1:S14-22. Epub 2013 Jul 1.

Institute of Cancer Research, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.05.012DOI Listing
October 2013

Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress.

Cancer Lett 2013 Oct 22;339(1):49-59. Epub 2013 Jul 22.

Haemato-Oncology Research Unit, Division of Molecular Pathology, Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835130054
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2013.07.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778988PMC
October 2013

The impact of response on bone-directed therapy in patients with multiple myeloma.

Blood 2013 Oct 23;122(17):2974-7. Epub 2013 Aug 23.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-04-498139DOI Listing
October 2013

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

Leuk Lymphoma 2013 Sep 23;54(9):1975-81. Epub 2013 Jan 23.

Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.760736DOI Listing
September 2013

Improved risk stratification in myeloma using a microRNA-based classifier.

Br J Haematol 2013 Aug 30;162(3):348-59. Epub 2013 May 30.

Section of Haemato-Oncology, Institute of Cancer Research, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12394DOI Listing
August 2013

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

Blood 2013 Jul 22;122(2):219-26. Epub 2013 May 22.

Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, Cotswold Rd, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-03-487884DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709654PMC
July 2013

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

Br J Haematol 2013 Apr 29;161(2):291-4. Epub 2013 Jan 29.

Division of Molecular Pathology, Haemato-Oncology Research Unit, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12218DOI Listing
April 2013

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.

Blood 2013 Apr 22;121(17):3413-9. Epub 2013 Feb 22.

Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-12-47
Publisher Site
http://dx.doi.org/10.1182/blood-2012-12-471888DOI Listing
April 2013

Understanding the molecular biology of myeloma and its therapeutic implications.

Expert Rev Hematol 2012 Dec;5(6):603-17

The Institute of Cancer Research, Brookes Lawley Building, 15 Cotswold Road, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.12.51DOI Listing
December 2012